CA3242280A1 - Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody - Google Patents
Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibodyInfo
- Publication number
- CA3242280A1 CA3242280A1 CA3242280A CA3242280A CA3242280A1 CA 3242280 A1 CA3242280 A1 CA 3242280A1 CA 3242280 A CA3242280 A CA 3242280A CA 3242280 A CA3242280 A CA 3242280A CA 3242280 A1 CA3242280 A1 CA 3242280A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- methods
- amyloid beta
- tau
- beta protofibril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291315P | 2021-12-17 | 2021-12-17 | |
| PCT/IB2021/000937 WO2023111618A1 (en) | 2021-12-17 | 2021-12-17 | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| IBPCT/IB2021/000937 | 2021-12-17 | ||
| US63/291,315 | 2021-12-17 | ||
| PCT/US2022/079509 WO2023114586A1 (en) | 2021-12-17 | 2022-11-08 | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242280A1 true CA3242280A1 (en) | 2023-06-22 |
Family
ID=84387973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242280A Pending CA3242280A1 (en) | 2021-12-17 | 2022-11-08 | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250051427A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4448005A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024547001A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240115910A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022410770A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242280A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007288A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023114586A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025019457A1 (en) | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025049938A1 (en) * | 2023-08-31 | 2025-03-06 | Florida Atlantic University Board Of Trustees | Non-invasive delivery method of antibodies to the brain for treatment of brain diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
| WO2020023530A2 (en) * | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN112187401B (zh) | 2019-07-03 | 2022-06-14 | 华为技术有限公司 | 多时间单元传输方法及相关装置 |
| US11877315B2 (en) | 2020-09-15 | 2024-01-16 | Qualcomm Incorporated | Wireless device digital beamforming capability indication |
-
2022
- 2022-11-08 WO PCT/US2022/079509 patent/WO2023114586A1/en not_active Ceased
- 2022-11-08 CA CA3242280A patent/CA3242280A1/en active Pending
- 2022-11-08 JP JP2024536189A patent/JP2024547001A/ja active Pending
- 2022-11-08 EP EP22817858.8A patent/EP4448005A1/en active Pending
- 2022-11-08 AU AU2022410770A patent/AU2022410770A1/en active Pending
- 2022-11-08 MX MX2024007288A patent/MX2024007288A/es unknown
- 2022-11-08 KR KR1020247023419A patent/KR20240115910A/ko active Pending
- 2022-11-08 US US18/720,518 patent/US20250051427A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250051427A1 (en) | 2025-02-13 |
| EP4448005A1 (en) | 2024-10-23 |
| WO2023114586A1 (en) | 2023-06-22 |
| AU2022410770A1 (en) | 2024-06-13 |
| KR20240115910A (ko) | 2024-07-26 |
| MX2024007288A (es) | 2024-06-28 |
| JP2024547001A (ja) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| WO2021262910A3 (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| MX2022013163A (es) | Anticuerpo contra nectin-4 y aplicacion del mismo. | |
| WO2020132658A3 (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2023280092A9 (zh) | 抗体药物偶联物及其应用 | |
| BR112021019107A2 (pt) | Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos | |
| WO2004113277A8 (en) | Methods and compositions for treating amyloid-related diseases | |
| WO2019217145A8 (en) | Anti-dll3 antibodies and uses thereof | |
| WO2022034524A3 (en) | Antibodies against ilt2 and use thereof | |
| EP3907223A4 (en) | PROCESS FOR PRODUCTION OF DRUG TOXIN PNU-159682 AN ANTIBODY DRUG CONJUGATE AND INTERMEDIATE THEREOF | |
| EP4406555A3 (en) | Antibodies to pmel17 and conjugates thereof | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| MX2024011805A (es) | Nuevos anticuerpos anti-fgfr2 | |
| MX2024007288A (es) | Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. | |
| WO2021011673A3 (en) | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease | |
| MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
| BR112019008359A2 (pt) | método para tratamento da doença de alzheimer, e, composição farmacêutica. | |
| WO2021226321A3 (en) | Anti-tumor associated antigen antibodies and uses thereof | |
| MX2022008901A (es) | Conjugados de proteinas-compuestos antivirales. | |
| WO2023081194A3 (en) | Methods for treating alzheimer's disease | |
| WO2021151180A3 (pt) | Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas | |
| WO2024186859A3 (en) | Anti-tl1a antibody compositions and methods of treatment for sarcoidosis | |
| BR112023000455A2 (pt) | Tratamento de doença inflamatória que usa anticorpos de fator antitecidual |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241217 |